BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:56 PM
 | 
Apr 05, 2010
 |  BC Extra  |  Top Story

FDA posts Daxas briefing documents

On Wednesday, FDA will ask members of its Pulmonary-Allergy Drugs Advisory Committee to discuss the efficacy and "serious safety issues" associated with Daxas roflumilast, a compound from Forest Laboratories Inc. (NYSE:FRX) and Nycomed (Zurich, Switzerland) for chronic obstructive pulmonary disease (COPD). In briefing documents released ahead of the meeting, FDA concluded the oral phosphodiesterase-4 (PDE-4)...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >